The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC: ESALY) and Biogen’s ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

Stocks rebounded after last week’s slide as a rout in Treasuries abated after 10-year yields approached 4.5%, with traders keeping a close eye on news around President-elect Donald Trump’s ...

Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

INCHEON, South Korea and CAMBRIDGE, MA, USA I November 18, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

Stocks edged higher after their worst week since early September as the selloff in Treasuries abated, with traders keeping a close eye on news around President-elect Donald Trump’s administration.

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...